Earnings digests and industry comparisons for Japan's biggest listed companies.
237 reports(page 7 of 20)
Disco reported first-half individual sales of 213.6 billion yen, a 32.8% year-on-year increase. The result exceeded the company's recent execution forecast of 201.1 billion yen by 106.2%, driven by strong equipment demand for generative AI.
Ricoh resolved on Oct 6 to launch a strategic review led by independent directors. The move aims to fundamentally restructure profits and raise corporate value.
Rohto revised its fiscal year 2030 sales target up by 29 billion yen to 444 billion yen. The company is also adopting rolling forecasts instead of fixed targets through 2031.
Property renewal leader Tosei has revised its full-year forecast for the fiscal year ending November 2026, raising operating profit significantly while increasing the final dividend to 58 yen. Although sales revenue is expected to decline, improved margins and enhanced shareholder returns underscore a strategic pivot toward higher value.
Shionogi will acquire US biotech IntraBio for $2 billion, securing global rights to the rare disease drug AQNEURSA. This strategic move establishes a new high-value revenue pillar alongside its infectious disease business.
Kansai Electric will raise basic charges for low-voltage customers in the capital region by approximately 29% starting November 1. The adjustment reflects transmission fees and signals a shift toward higher fixed costs. This move pushes rates above industry norms as the utility seeks cost recovery.
Takara Holdings announced it will transfer a 70% stake in Takara Logistics Systems to Central Warehouse on Oct 5, 2026. This move aligns with its strategy to focus resources on core alcohol business operations.
Nihon M&A Center disclosed that its mid-term dividend for the fiscal year ending March 2026 exceeded the legal distributable amount by approximately 833 million yen. The company stated it will not demand repayment from shareholders and is establishing a third-party committee to investigate the internal control failure.
Otsuka Holdings subsidiary Daikochi Kogyo has started the New Drug Application process for its lung cancer drug Zeprelertinib in the United States. The company aims to complete the application by late 2026, leveraging an expedited review program to potentially accelerate market entry.
Rohto updated its long-term strategy on Oct. 2, targeting 4,640 billion yen in sales by fiscal year 2031 with a 12.9% operating margin. The pharma giant also committed to significantly increasing its dividend payout ratio to drive shareholder value.
JAPEX has completed the acquisition of full ownership in Fundare, a US tight oil and gas asset holding company, for $2.78 billion. The deal aims to leverage proximity to existing Verdad assets to drive efficiency and reduce unit costs.
K Line has completed the cancellation of its treasury stock, effectively reducing issued shares by nearly 7%. The shipping giant executed this move on Oct 2 following a board resolution in September.
